Aardvark Therapeutics' stock dropped 56% after the company stopped its Phase 3 trial for ARD-101, a drug for Prader-Willi Syndrome, due to serious cardiac safety risks. This sudden halt and safety issues led to a shareholder rights firm launching an investigation into whether Aardvark misled investors about the drug's safety and FDA communications. The company no longer expects trial results in Q3 2026, and analysts have cut price targets sharply. Investors with losses are encouraged to seek legal help as the investigation continues.
Citytv has announced the renewal of its popular series Hudson & Rex for a new 12-episode season, with production beginning in June 2026 in St. John's, Newfoundland. John Reardon returns as detective Charlie Hudson, reuniting with his canine partner R...
Citytv has announced the renewal of its popular series Hudson & Rex for a new 12-episode season starting production in June 2026 in St. John's, Newfoundland. John Reardon returns as Detective Charlie Hudson, reuniting with his canine partner Rex, alo...
A NordLayer report reveals that 82% of IT professionals experienced web-based security incidents in the past year, with half describing the impact as moderate or severe. Increased use of BYOD policies, remote work, and SaaS tools expands attack surfa...
Medidata unveiled its next-generation AI-powered imaging solution at ASCO 2026, enhancing clinical trial efficiency by speeding up protected health information redaction by 32% and achieving over 97% accuracy in anatomy verification. This technology ...
CredFin, Inc. has partnered with The Agent Underground, led by Rob Thomas, to help independent insurance agents access capital for acquisitions and growth amid AI-driven industry disruption. With AI threatening traditional agent roles and acceleratin...
